Cognitive complaints and cognitive impairment in patients with chronic daily headache
Comorbidities in chronic daily headache (CDH) include emotional disorders (depression, anxiety), insomnia, and musculoskeletal pain at other sites. In CDH, the most common type is a subjective (according to patients themselves) and/or objective (based on the results of cognitive tests) reduction i...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2017-12-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/796 |
| Summary: | Comorbidities in chronic daily headache (CDH) include emotional disorders (depression, anxiety), insomnia, and musculoskeletal pain at other sites. In CDH, the most common type is a subjective (according to patients themselves) and/or objective (based on the results of cognitive tests) reduction in cognitive functions, which can be caused by emotional disorders, insomnia and/or brain diseases, and a negative effect of chronic pain on cognitive functions.Objective: to analyze cognitive complaints and their changes in patients with CDH.Patients and methods. Subjective complaints and cognitive functions were evaluated in 90 patients (76 women and 14 men) aged 23 to 78 years (mean age, 46.7±12.0 years) with primary forms of CDH according to the Montreal Cognitive Assessment (MCA) for 12 months. The majority (68.9%) of patients with CHD complained of diminished memory; however, its mild disorders (25– 26 MCA scores) were found in only a small proportion (23.3%). All patients with subjective diminished memory were ascertained to have neurotic disorders (depression, anxiety disorder) and/or insomnia or a concurrence of mental disorder and insomnia.Results and discussion. All the patients received treatment options, including optimal pharmacotherapy for headache and concomitant diseases, an educational conversation, cognitive- behavioral therapy, and therapeutic exercises. In cognitive impairment (CI), cognitive training was used and Ginkgo biloba extract (EGb 761®) prescribed; in sleep disorders, sleep hygiene rules were explained. Therapy declined the mean number of headache days a month from 29.1±2.03 (at baseline) to 9.3±9.35 (at 12-month follow-up) (p=0.002); while the subjective complaints regressed in the majority of patients; mild MCA changes persisted only in 6.7% of the patients. Management tactics for CHD patients having mild CI and cardiovascular risk factors and the use of EGb 761® to improve cognitive functions were considered.Conclusion. It has been ascertained that in many cases, CI is associated with emotional disorders and insomnia, as well as with pathophysiological mechanisms of chronic pain itself; CI in some patients has a vascular origin. The use of combined treatment programs can promptly and effectively reduce the frequency of headache and improve cognitive functions. EGb 761® (Tanakan®) has a beneficial effect on subjective CI and mild CI. |
|---|---|
| ISSN: | 2074-2711 2310-1342 |